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Bilirubin bindingbiological functions and the serum albumin level is related to prognosis in
advanced liver disease. Oxidative stress is believed to play an important role in the pathogenesis of liver
failure. The aim of the present study was to characterize oxidative modiﬁcation of albumin in patients with
various degrees of liver failure and to investigate implications for its binding function. Patients with liver
cirrhosis (n=10), acute-on-chronic liver failure (n=8) and healthy controls (n=15) were included in the study.
Three fractions of albumin were separated by HPLC according to the redox state of cysteine-34 and detected
by ﬂuorescence as well as UV absorption. Carbonyl groups were measured as a marker of oxidative
modiﬁcation in plasma proteins and, by western blotting, on albumin. Progressive oxidative modiﬁcation of
albumin was found with increasing severity of liver failure indicated by an increased content of carbonyl
groups and oxidation of cysteine-34. Fluorescence properties of albumin were altered by oxidation and, in
patients with acute-on-chronic liver failure, by high plasma levels of bilirubin. This alteration of albumin
ﬂuorescence by bilirubin provides evidence for a preferred binding of bilirubin to the fully reduced form of
albumin.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionAlbumin, a 66.5 kDa protein, is quantitatively the most important
plasma protein [1]. It is the main determinant of plasma oncotic
pressure and exhibits many other biological functions, such as
transport of endogenous and exogenous compounds, modulation of
capillary permeability, neutrophil adhesion and activation, hemostasis
and free radical scavenging (for review see [2]). The serum albumin
level is an important prognostic factor in advanced liver disease [3]. Its
main therapeutical uses includemaintenance of intravascular volume,
prevention of circulatory dysfunction and hepatorenal syndrome and,
more recently in extracorporeal liver support, removal of potentially
toxic substances accumulating in liver failure (for review see [4]).
Albumin is themajorextracellular sourceof reduced sulfhydryl groups,
which are potent scavengers of reactive oxygen and nitrogen species [5].
Depending on the redox state, there are three major species of albumin:
mercaptalbumin (HMA) with a free thiol group on cysteine-34,
nonmercaptalbumin1 (HNA1)with cysteine, homocysteine or glutathione
bound by a disulﬁde bond and nonmercaptalbumin2 (HNA2) withMA, human mercaptalbumin;
nonmercaptalbumin2; PBS,
hemistry, Harrachgasse 21/II,
316 380 9610.
l rights reserved.cysteine oxidized to sulﬁnic or sulfonic acid [6,7]. HMA and HNA1 are in
a dynamic exchange with small thiol-containing compounds and
disulﬁdes in the blood [8]. The sulfenic acid state was described as a
reactive intermediate in the formation of HNA1 [9,10]. Protein sulﬁnic and
sulfonic acids have long been considered to be irreversibly oxidized but
recently reversible oxidation/reduction of these species in redox regula-
tion has been described [11,12].
Oxidative stress is believed to play a major role in the pathogenesis
of acute-on-chronic liver failure (ACLF) [13]. Sogami et al. described
decreased relative amounts of HMA in patients with various liver
diseases as compared to healthy controls [14]. This was conﬁrmed by
Watanabe et al., who also reported an increase of oxidized albumin
with severity of liver disease [15]. Oxidized albumin shows altered
binding capacities for several substances used to assess albumin
function: Decreased bilirubin binding was reported for in vitro
oxidized albumin [16] and decreased binding of dansylsarcosine was
found in plasma of patients with end-stage liver disease [17,18]. We
recently reviewed the relation of oxidative modiﬁcation of albumin to
its binding properties [19]. However, the pathophysiological impact
and the clinical implications of albumin modiﬁcation in liver disease
have not yet been studied in detail and no data exist on the redox state
of albumin in ACLF, a condition with liver failure as well as secondary
end-organ failure associated with poor prognosis.
The aim of the present study was to investigate oxidative
modiﬁcation of albumin and its relation to physiological properties
of albumin in patients with advanced liver disease.
Fig. 1. Representative western blots of carbonyl groups in albumin (a). Plasma proteins were
separated in duplicate gels and stained as described in Materials and methods section. A,
protein stain; B, carbonyl stain. Blotted albumin was visualised after derivatization with
dinitrophenylhydrazine. The integrated density of the carbonyl-stained albumin bands of 6
patients of each group were determined and the means+SD are given (b). LC, liver cirrhosis;
ACLF, acute-on-chronic liver failure.
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2.1. Patients
Eighteen patients with liver cirrhosis admitted to the Department of Internal
Medicine, Medical University of Graz, between March 2003 and May 2005 were
enrolled in this study. The study population comprised 8 consecutive patients with
ACLF being evaluated for extracorporeal liver support as well as 10 patients with liver
cirrhosis (LC) who were candidates for liver transplantation. ACLF was deﬁned as
acute deterioration of liver function over a period of 2–4 weeks, associated with a
precipitating event, with jaundice and either hepatic encephalopathy or hepatorenal
syndrome, and with a high SOFA (Sepsis-related Organ Failure Assessment) or APACHE
II (Acute Physiology and Chronic Health Evaluation II) score [20]. The study protocol was
approved by the Ethics Committee of the Medical University of Graz and informed
consent was obtained in accordance with the Declaration of Helsinki. Blood samples
were immediately centrifuged at 4 °C and plasma aliquots were stored at −70 °C until
batch analysis. Bilirubin, albumin, creatinine, prothrombin time (international normal-
ized ratio, INR), and C-reactive protein (CRP) were routinely assessed. To estimate
severity of liver disease, Child–Pugh score and the model for end-stage liver disease
(MELD) were calculated [3,21]. Plasma samples from 15 age and sex-matched healthy
blood donors were used as controls.
2.2. Albumin analysis
Albumin was fractionated by high performance liquid chromatography to give
three peaks according to cysteine-34 in the free sulfhydryl form (HMA), as a mixed
disulﬁde (HNA1) or in a higher oxidation state (HNA2) as previously described [22].
Plasma samples were diluted 1:100 with 0.1 M sodium phosphate, 0.3 M sodium
chloride, pH 6.87, ﬁltered through a Whatman 0.45 µm nylon ﬁlter (Bartelt Labor- &
Datentechnik, Graz, Austria). Thereafter, 20 µL were injected into the HPLC system.
Separation was performed using a Shodex Asahipak ES-502N 7C anion exchange
column (7.5×100 mm, Bartelt Labor- & Datentechnik, Graz, Austria) with 50 mM
sodium acetate, 400 mM sodium sulfate, pH 4.85 as mobile phase. For elution a
gradient of 0 to 6% ethanol and a ﬂow rate of 1 mL/min applied by a FLUX Rheos 4000
gradient pump (Spectronex, Vienna, Austria) were used. The columnwas kept at 35 °C.
Detectionwas carried out by ﬂuorescence at 280/340 nm and UV absorption at 280 nm
in series with a Jasco 821FP ﬂuorescence detector (Spectronex, Vienna, Austria) and a
Waters 2487 UV/VIS detector (Waters, Vienna, Austria), respectively. Quantiﬁcation
was based on peak heights determined by EZ Chrom Elite chromatography software
(VWR, Vienna, Austria). The ﬂuorescence/UV absorption ratio was obtained as the
ratio of the peakheights from the ﬂuorescence and UV chromatograms. A commercial
20% albumin solution obtained from Behring GmbH (Vienna, Austria) was used as a
control.
2.3. Quantitative carbonyl protein determination
Quantiﬁcation of carbonyl groups using an ELISA assay was carried out as
described [23,24] with slight modiﬁcations. In brief, oxidized human serum albumin
was used as standard. Oxidized albumin standards were prepared from a commercial
20% albumin solution (Behring, Vienna, Austria) as described in [23] using iron ions/
ascorbic acid as oxidizing agents after removing the stabilizer by intense dialysis.
Standards and samples were diluted to give a ﬁnal protein concentration of 4 mg/mL.
For protein derivatization, 45 µL dinitrophenylhydrazine solution (10 mM dinitro-
phenylhydrazine in 6 M guanidine hydrochloride, 0.5 M potassium phosphate buffer,
pH 2.5) were mixed with 15 µL sample and incubated for 45 min, vortexing every
15 min. Afterwards, 5 µL of each solution was added to 995 µL PBS (phosphate
buffered saline, 10 mM, pH 7.4). Duplicate 200 µL aliquots were added to wells of a
Nunc Immuno Plate Maxisorb. Plates were incubated over night at 4 °C and then
washed 4 times with 300 µL PBS containing 0.05% Tween20 using the ELx405
microplate washer (Bio-Tek, Vermont, USA). Then, 200 µL PBS containing 0.2% I-Block
and anti-dinitrophenylhydrazine-horseradish peroxidase antibody (1:1000) were
added to each well and incubated at 37 °C for 1 h. After an additional washing step,Table 1
Patient characteristics
Age
(y)
INR Albumin
(g/L)
Bilirubin
(mg/L)
Creatinine
mg/L
CRP
(mg/L)
MELDa Child–
Pugh
score
ACLF
(n=8)
58±4 2.17±0.73c 29.3±3.4b 283±91b,c 23±18b 70±42b,c 33±11c 12±1c
LC (n=10) 57±6 1.3±0.11 32.4±6.9b 23±16b 12±7b 13±18b 13±4 9±2
CONTROL
(n=15)
55±5 n.a. 47.6±2.4 6±3 8±1 2±2 n.a. n.a.
INR, international normalized ratio; CRP, C-reactive protein. n.a., not available.
aMELD scorewas obtained using theMELD calculator at theMayo Clinic website (http://
www.mayoclinic.org/gi-rst/mayomodel5.html).
bpb0.05 vs. controls.
cpb0.05 vs. LC.200 µL super signal ELISA maximum sensitivity substrate (Pierce, Rockford, USA) were
added to each well. Light emission was measured on a chemiluminescence reader
(Lumistar, BMG, Germany).
2.4. Carbonyl protein detection by western blot
Protein derivatization was carried out as described for ELISA. Excess guanidine
hydrochloride was eliminated by Ultrafree Centrifugal Filter (Millipore, Billerica, USA).
Subsequently, protein content was determined by BCA protein assay (Pierce, Rockford,
USA) and 10 µg was separated electrophoretically on a 5–12.5% polyacrylamide gel. Two
gels were run simultaneously using the Mini-Protean 3 system (BioRad, Hercules, USA).
One gel was stained with PhastGel Blue R (Pharmacia, Uppsala, Sweden) and the other
one was transferred on a Immuno Blot PVDF membrane. The electrophoretical protein
transfer was carried out using the Trans-Blot SD semi-dry electrophoretic transfer
system (BioRad, Hercules, USA). Afterwards, unspeciﬁc binding sites were blocked for
3 h in 40 mL PBS containing 0.2% casein. Thereafter, the membrane was incubated for
1 h with 40 mL PBS containing 0.2% casein and anti-dinitrophenylhydrazine-
horseradish peroxidase antibody (1:4000). Three washing steps followed, each
10 min, with 40 mL PBS containing 0.05% Tween20. Afterwards, the membrane was
developed with super signal western maximum sensitivity substrate (Pierce, Rockford,
USA) and the PVDF membrane was scanned using the AlphaImager Imaging system
(Alpha Innotech Corporation, San Leandro, USA).
2.5. Statistics
Results are given as mean±SD unless indicated otherwise. Groups were compared
with Student's t-test. Pearson's correlation coefﬁcient was used to assess relationships
between variables.
3. Results
The characteristics of the study population are shown in Table 1. The
severity of the disease is indicated by the MELD (model for end-stage
liver disease) and the Child–Pugh score. As expected, the plasma levels
of albumin were signiﬁcantly decreased in patients with severe liver
disease while the bilirubin levels were increased. The content of car-
bonyl groups in plasma proteins was slightly increased in LC (0.22±
0.08 µmol/g protein, pb0.05) but markedly increased in ACLF (0.68±
0.29 µmol/g protein, pb0.05) compared to healthy controls (0.18±
0.04 µmol/g protein). Using western blot to investigate the appearance
of carbonyl groups in albumin, we could show that albumin is a target
Fig. 2. Representative chromatograms. Albumins in plasma from a control subject
(a), from a LC patient (b), from an ACLF patient (c) and from a commercial albumin
solution (d) were separated by HPLC. Peaks indicated as 1, 2 and 3 represent HMA, HNA1
and HNA2, respectively. F and UV indicate ﬂuorescence and ultraviolet detection,
respectively.
Fig. 3. Ratio of ﬂuorescence intensity/UV absorbance in albumin fractions after HPLC
separation. Mean values±SD are shown. Grey bars, controls; black bars, liver cirrhosis;
white bars, acute-on-chronic liver failure.
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severely increased content of carbonyl groups. (Fig.1). On densitometric
analysis (n=6 per group), the banddensitywas signiﬁcantly increased in
ACLF vs. LC and controls (pb0.05)while the slight increase in LCpatients
vs. controls was not signiﬁcant (Fig. 1).
We routinely determine the distribution of albumin to HMA, HNA1
and HNA2 by HPLC with ﬂuorescence detection. However, using
samples from ACLF patients we found that the results obtained by
ﬂuorescence detection differ considerably from those obtained by UV
detection (Fig. 2c). In a commercial albumin solution UV and
ﬂuorescence detection gave the same results (Fig. 2d). This is also
true for samples from healthy subjects (Fig. 2a). The distribution of
albumin species in patients and controls obtained by HPLC with UV
detection are presented in Table 2. While HMA was signiﬁcantly
decreased, both oxidized species were signiﬁcantly increased in LC
and ACLF patients.Table 2
Percentages of albumin species in patients and controls obtained by HPLC with UV
detection
HMA HNA1 HNA2
% % %
ACLF 42.7±10.0a 41.4±7.4a 15.4±3.4a
LC 53.3±5.3a 39.6±6.1a 7.5±2.4a
Control 65.1±4.2 30.8±4.0 4.1±1.1
apb0.05 compared to controls.We further investigated the relation of the ﬂuorescence intensity to
UV absorbance in the chromatograms of the three albumin species
derived from controls, LC and ACLF patients (Fig. 3). In control samples
HMA and HNA1 gave the same ratio of ﬂuorescence/UV absorbance.
In HNA2, however, the ratio dropped to 67% of the value for HMA
(pb0.001), indicating decreased ﬂuorescence intensity in relation to
UV absorbance. In LC samples HNA1 had a slightly higher (pb0.001)
and HNA2 a lower (pb0.05) signal ratio compared to HMA. In ACLF
samples these differences were even more pronounced. Comparing
the same albumin species of different patient groups we found that
HNA2 shows the same low signal ratio in both patient groups and
controls. For HNA1, values in ACLF samples were decreased by 26%
(pb0.001) while LC samples were not different from controls. For
HMA, LC samples showed a signal ratio which was about 10% lower
than that of controls (pb0.001) and ACLF samples had a ﬂuorescence
intensity /UV absorbance ratio of only 36% compared to control sam-
ples (pb0.001).
The ratio of ﬂuorescence intensity/UV absorbance decreased with
increasing bilirubin concentrations (Fig. 4). When extrapolating the
ﬂuorescence intensity/UV absorbance ratio to a bilirubin level of 0,
HMA and HNA1 gave similar numbers (268 and 278, respectively),
but the value for HNA2 was distinctly lower (196). The correlationFig. 4. Fluorescence of albumin species depends on the plasma bilirubin concentration.
The ratio of ﬂuorescence intensity/UV absorbance on HPLC is plotted against plasma
bilirubin concentration. (●), HMA; (▵), HNA1; (○), HNA2.
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plasma bilirubin were 0.97 (pb0.0001) in HMA, 0.91 (pb0.0001) in
HNA1 and 0.41 (pb0.05) in HNA2.
Correlation analysis revealed that the percentages of HMA, HNA1
and HNA2 as well as the carbonyl content were signiﬁcantly related to
bilirubin (pb0.05). In addition, HNA2 and carbonyl content correlated
with MELD, Child–Pugh score and prothrombin time (international
normalized ratio). For creatinine no signiﬁcant correlation was found.
4. Discussion
Structure and function of albumin are impaired in advanced liver
disease by different mechanisms: plasma levels are decreased due to
reduced synthesis, albumin is oxidativelymodiﬁed, andbinding sites are
occupied by high levels of bilirubin. We herein demonstrate that, in
advanced liver disease, severe oxidative damage of albumin is associated
with decreased binding of bilirubin.
Carbonyl groups in proteins are a well established marker of
oxidative stress [25,26]. The carbonyl content of plasma proteins was
signiﬁcantly increased in our ACLF patients. Which of the plasma
proteins is the most sensitive to oxidative modiﬁcation has so far been
a matter of debate [27,28]. However, we could show by western blot
analyses that albumin is a targetof carbonylation. The extentof oxidative
modiﬁcation depends on the severity of the disease. In patients with LC,
albumin fractions were signiﬁcantly shifted from HMA to HNA1 and
HNA2, while the increase of carbonyl groups was about 20% and not
signiﬁcant. In patients with ACLF the percentage of HNA1 was further
increased, the percentage of HNA2 was increased up to fourfold com-
pared to controls and carbonyl groups were about three times the
control value.
As binding and transport of different compounds is an important
function of albumin, oxidative damage of albumin is of high clinical
relevance. However, binding data of albumin frompatientswith severe
liver disease are scarce and have to be interpretedwith cautionmainly
for two reasons: (i) isolation of albumin for binding experiments is
laborious and may produce artifacts and (ii) binding studies with
plasma from patients with severe liver dysfunction are hampered by
the presence of high levels of other ligands such as bilirubin that make
it impossible to distinguish between altered binding due to differences
in albumin structure and effects due to the presence of these ligands.
Increases of bilirubin levels may be hundredfold in ACLF patients. In
healthy subjects plasma contains about 1 mol bilirubin per 100 mol
albumin. In contrast, in ACLF patients the molar ratio of bilirubin to
albumin ranges around 1:1 as estimated from theirmeanplasma levels
observed in our study.
We found differences in the relation of ﬂuorescence intensity to UV
absorption in HMA, HNA1 and HNA2. The reason for impaired
ﬂuorescence may be two-fold: ﬁrst, oxidative damage of albumin was
shown to reduce its ﬂuorescence intensity [29]. Second, reduced
ﬂuorescence intensity may be due to quenching by various other
compounds accumulating in plasma of patients with liver failure,
including bilirubin [26]. In ACLF patients both factors are present: (i)
albumin is severely oxidized as monitored by the percentage of HNA2
and carbonyl groups and (ii) the levels of bilirubin are extremely high.
The ﬂuorescence/UV absorbance ratio of the highly oxidized HNA2 is
essentially the same in both patient groups and controls (Fig. 3) and
hence independent from the bilirubin content of the plasma. Therefore
the lower ratio of HNA2 compared toHMAcannot bedue to a quenching
effect of bilirubin but ismost likely achieved by oxidative damage. HNA1
and HMA show similar ratios in controls and LC patients, but in ACLF
patients the ratio is decreased for HNA1 and evenmore forHMA.HMA is
a reduced form of albumin with respect to cysteine-34 and it may be
expected that also the other domains of themolecule are less oxidatively
damaged compared to HNA. Since ACLF patients showed the highest
plasma concentrations of bilirubin, the severely decreased ﬂuorescence
of HMA from ACLF patients can be attributed to the high concentrationsof the ﬂuorescence quencher bilirubin rather than to oxidative damage.
In ACLF patients HMA has the lowest ﬂuorescence/UV absorption ratio
compared to HNA1 and HNA2, indicating that ﬂuorescence quenching
by bilirubinmainly takes place in HMA. Thuswe conclude that oxidative
damage impairs bilirubin binding of albumin and HMA has a higher
afﬁnity for bilirubin compared to HNA1 and HNA2.
This interpretation is supported by the correlation of the ﬂuo-
rescence/UV absorbance ratio to the bilirubin concentration (Fig. 4).
Increasing bilirubin suppresses ﬂuorescence only slightly in HNA1 and
HNA2. The steeper slope for HMA indicates a preferred binding of
bilirubin to the reduced form of albumin. In contrast, HNA2 shows a
lower ﬂuorescence intensity even in the extrapolated absence of
bilirubin and the dependence of the ratio on bilirubin is much weaker.
These data suggest an increasing bilirubin binding afﬁnity in the order
HNA2bHNA1bHMA. The decreased percentages of HMA aswell as the
lower total albumin concentrations in plasma of patients provide the
pathophysiological basis for impaired albumin function in advanced
liver disease.
The clinical relevance of albumin dysfunction in advanced liver
disease is supported by studies showing reduction in severity of hepa-
tic encephalopathy and improved survival of cirrhotic patients with
spontaneous bacterial peritonitis and hepatorenal syndrome treated
with albumin infusion [30–32]. Infusion of albumin [33] as well as
albumin dialysis using the Molecular Adsorbents Recirculating System
(MARS) [18,34–37] have been shown to improve the circulatory
dysfunction as evidenced by an increase in mean arterial pressure and
systemic vascular resistance. This improvement in systemic hemody-
namicsmight be due to a reduction in vasodilation following removal of
nitric oxide and its metabolites [38] which results in deactivation of the
neurohumoral systems and a decrease in plasma levels of renin,
aldosterone, norepinephrine and vasopressin [33,39,40].
In summary, our ﬁndings indicate that albumin is oxidatively
modiﬁed in patients with advanced liver disease depending on its
severity. While oxidation is relatively mild in liver cirrhosis, severe
modiﬁcations occur in ACLF. As bilirubin is preferentially bound by the
fully reduced form of albumin, impaired binding of bilirubin and other
ligands is likely to occur in liver cirrhosis and more so in ACLF.
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